Clinical Trial Update: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

An ongoing Phase 1 trial evaluating Ac-225-PSMA-62 for oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer, sponsored by Eli L…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Ac-225-PSMA-62 (Actinium-225 labeled PSMA-62)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING